

## VI. Implementation of Adjusted Fee Schedule

### A. Application Fees

The appropriate application fee established in the new fee schedule must be paid for any application or supplement subject to fees under PDUFA that is received after September 30, 2007. Payment must be made in U.S. currency by check, bank draft, or U.S. postal money order payable to the order of the Food and Drug Administration. Please include the user fee ID number on your check. Your payment can be mailed to: Food and Drug Administration, P.O. Box 70963, Charlotte, NC 28272-0963.

If checks are to be sent by a courier that requests a street address, the courier can deliver the checks to: Wachovia Bank, Attn: Food and Drug Administration Lockbox 70963, 1525 West WT Harris Blvd., rm. NC0810, Charlotte, NC 28262. (Note: This Wachovia Bank address is for courier delivery only.)

Please make sure that the FDA post office box number (P.O. Box 70963) is written on the check. The tax identification number of the Food and Drug Administration is 53-0196965.

Wire transfer payment may also be used. The routing and transit number is 021030004 and the account number is 75060099. Please include, as the reference, the NDA/BLA number and the user fee ID number.

FDA is in the process of implementing alternate Web-based payment methods. For more information on these payment options and when they will be available, please visit FDA's Web site at <http://www.fda.gov>, select the appropriate user fee type, and click on "User Fee Cover Sheet."

### B. Establishment and Product Fees

FDA will issue invoices for establishment and product fees for FY 2008 under the new fee schedule in October 2007. Payment will be due 30 days from the date of the invoice. FDA will issue invoices in November 2008 for any products and establishments subject to fees for FY 2008 that qualify for fees after the October 2007 billing.

Dated: October 4, 2007.

**Randall W. Lutter,**

*Deputy Commissioner for Policy.*

[FR Doc. 07-5052 Filed 10-9-07; 12:06 pm]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2007D-0309]

#### Draft Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document: Electrocardiograph Electrodes; Availability; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of October 4, 2007 (72 FR 56771). The document announced the availability of a draft guidance entitled "Class II Special Controls Guidance Document: Electrocardiograph Electrodes." The document was published with an incorrect docket number. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:** Joyce A. Strong, Office of Policy (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7010.

**SUPPLEMENTARY INFORMATION:** In FR Doc. E7-19578, appearing on page 56771 in the **Federal Register** of Thursday, October 4, 2007, the following correction is made:

1. On page 56771, in the third column, in the heading of the document, "[Docket No. 2007N-0309]" is corrected to read "[Docket No. 2007D-0309]".

Dated: October 5, 2007.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. E7-20183 Filed 10-11-07; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Notice of Availability of Draft Policy Documents for Comment

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Extension of requests for comments deadline.

**SUMMARY:** The Health Resources and Services Administration published a notice in the **Federal Register** of August 29, 2007, requesting comments on draft

Agency Guidance (Policy Information Notices (PINS)) to describe the policy and processes pertaining to requests from federally-funded health centers to change the scope of their Federal project. The PINS, "Defining Scope of Project and Policy for Requesting Changes," "Changes in Scope Requests: Policy for Adding a New Target Population," and "Specialty Services and Health Centers' Scope of Project," are available on the Internet at <http://bphc.hrsa.gov>.

**Correction:** In the **Federal Register** of August 29, 2007, FR Doc. E7-17092, on page 49724, in the first column, under **DATES**, the deadline for comments has been extended to October 19, 2007.

Dated: October 5, 2007.

**Dennis P. Williams,**

*Deputy Administrator.*

[FR Doc. E7-20171 Filed 10-11-07; 8:45 am]

BILLING CODE 4165-15-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).

A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.